Asymmetric Dimethyl Arginine As a Biomarker of Atherosclerosis in Rheumatoid Arthritis

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2018 Mar 27

PMID 29576746

Citations 10

Authors

Manuela Di Franco

Bruno Lucchino

Fabrizio Conti

Guido Valesini

Francesca Romana Spinelli

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease is the main cause of morbidity and mortality in rheumatoid arthritis (RA). Despite the advent on new drugs targeting the articular manifestations, the burden of cardiovascular disease is still an unmet need in the management of RA. The pathophysiology of accelerated atherosclerosis associated to RA is not yet fully understood, and reliable and specific markers of early cardiovascular involvement are still lacking. Asymmetric dimethylarginine is gaining attention for its implication in the pathogenesis of endothelial dysfunction and as biomarkers of subclinical atherosclerosis. Moreover, the metabolic pathway of methylarginines offers possible targets for therapeutic interventions to decrease the cardiovascular risk. The purpose of this review is to describe the main causes of increased methylarginine levels in RA, their implication in accelerated atherosclerosis, the possible role as biomarkers of cardiovascular risk, and finally the available data on current pharmacological treatment.

Citing Articles

Atherothrombotic Risk Factors in Patients With Rheumatoid Arthritis.

Sreekumar Sr M, Bobby Z, Negi V, Kommoju V, Sadanandan D Cureus. 2024; 16(5):e59818.

PMID: 38846255 PMC: 11156212. DOI: 10.7759/cureus.59818.

Pathogenesis of Extraarticular Manifestations in Rheumatoid Arthritis-A Comprehensive Review.

Mitrovic J, Hrkac S, Tecer J, Golob M, Ljilja Posavec A, Kolar Mitrovic H Biomedicines. 2023; 11(5).

PMID: 37238933 PMC: 10216027. DOI: 10.3390/biomedicines11051262.

TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis.

Szeremeta A, Jura-Poltorak A, Zon-Giebel A, Olczyk K, Komosinska-Vassev K J Clin Med. 2022; 11(14).

PMID: 35887981 PMC: 9320287. DOI: 10.3390/jcm11144213.

Determination of serum methylarginine levels by tandem mass spectrometric method in patients with ankylosing spondylitis.

Onmaz D, Isik K, Sivrikaya A, Abusoglu S, Gezer I, Abusoglu G Amino Acids. 2021; 53(9):1329-1338.

PMID: 34273021 DOI: 10.1007/s00726-021-03046-z.

Comparative Analysis of Compatibility Influence on Invigorating Blood Circulation for Combined Use of Panax Notoginseng Saponins and Aspirin Using Metabolomics Approach.

Sun Z, Wu H, Wu Y, Wang C, Wang Y, Hu S Front Pharmacol. 2021; 12:544002.

PMID: 33995000 PMC: 8120290. DOI: 10.3389/fphar.2021.544002.

References

Paiva H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O . Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism. 2003; 52(3):303-7. DOI: 10.1053/meta.2003.50048. View

del Rincon I, Williams K, Stern M, Freeman G, Escalante A . High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2002; 44(12):2737-45. DOI: 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-%23. View

Wang T, Chen W, Cheng W, Lin J, Chen M, Lee Y . Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2006; 98(8):1057-62. DOI: 10.1016/j.amjcard.2006.05.027. View

Dimitroulas T, Hodson J, Panoulas V, Sandoo A, Smith J, Kitas G . Genetic variations in the alanine-glyoxylate aminotransferase 2 (AGXT2) gene and dimethylarginines levels in rheumatoid arthritis. Amino Acids. 2017; 49(6):1133-1141. DOI: 10.1007/s00726-017-2413-6. View

Morales Y, Caceres T, May K, Hevel J . Biochemistry and regulation of the protein arginine methyltransferases (PRMTs). Arch Biochem Biophys. 2015; 590:138-152. DOI: 10.1016/j.abb.2015.11.030. View

Campuzano R, Moya J, Garcia-Lledo A, Tomas J, Ruiz S, Megias A . Endothelial dysfunction, intima-media thickness and coronary reserve in relation to risk factors and Framingham score in patients without clinical atherosclerosis. J Hypertens. 2006; 24(8):1581-8. DOI: 10.1097/01.hjh.0000239294.17636.27. View

Willeit P, Freitag D, Laukkanen J, Chowdhury S, Gobin R, Mayr M . Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015; 4(6):e001833. PMC: 4599532. DOI: 10.1161/JAHA.115.001833. View

Du F, Zhou J, Gong R, Huang X, Pansuria M, Virtue A . Endothelial progenitor cells in atherosclerosis. Front Biosci (Landmark Ed). 2012; 17(6):2327-49. PMC: 3368338. DOI: 10.2741/4055. View

Westphal S, Borucki K, Luley C, Martens-Lobenhoffer J, Bode-Boger S . Treatment with niacin lowers ADMA. Atherosclerosis. 2005; 184(2):448-50. DOI: 10.1016/j.atherosclerosis.2005.11.018. View

10.

Middleton J, Americh L, Gayon R, Julien D, Aguilar L, Amalric F . Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res Ther. 2004; 6(2):60-72. PMC: 400438. DOI: 10.1186/ar1156. View

11.

Di Franco M, Spinelli F, Metere A, Gerardi M, Conti V, Boccalini F . Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators Inflamm. 2012; 2012:347268. PMC: 3420101. DOI: 10.1155/2012/347268. View

12.

Sandoo A, Dimitroulas T, Hodson J, Smith J, Douglas K, Kitas G . Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. Rheumatology (Oxford). 2014; 54(7):1145-52. DOI: 10.1093/rheumatology/keu349. View

13.

Boger R, Maas R, Schulze F, Schwedhelm E . Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res. 2009; 60(6):481-7. DOI: 10.1016/j.phrs.2009.07.001. View

14.

Brunini T, Moss M, Siqueira M, Meirelles L, Rozentul A, Mann G . Inhibition of l-arginine transport in platelets by asymmetric dimethylarginine and N-monomethyl-l-arginine: effects of arterial hypertension. Clin Exp Pharmacol Physiol. 2004; 31(10):738-40. DOI: 10.1111/j.1440-1681.2004.04067.x. View

15.

Essouma M, Noubiap J . Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients. Biomark Res. 2015; 3:24. PMC: 4559887. DOI: 10.1186/s40364-015-0049-9. View

16.

Eid H, Reims H, Arnesen H, Kjeldsen S, Lyberg T, Seljeflot I . Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism. 2007; 56(4):464-9. DOI: 10.1016/j.metabol.2006.11.003. View

17.

Surdacki A . L-arginine analogs--inactive markers or active agents in atherogenesis?. Cardiovasc Hematol Agents Med Chem. 2008; 6(4):302-11. DOI: 10.2174/187152508785909429. View

18.

Dimitroulas T, Sandoo A, Hodson J, Smith J, Kitas G . In vivo microvascular and macrovascular endothelial function is not associated with circulating dimethylarginines in patients with rheumatoid arthritis: a prospective analysis of the DRACCO cohort. Scand J Clin Lab Invest. 2016; 76(4):331-7. DOI: 10.1080/00365513.2016.1177852. View

19.

Yang X, Chang Y, Wei W . Endothelial Dysfunction and Inflammation: Immunity in Rheumatoid Arthritis. Mediators Inflamm. 2016; 2016:6813016. PMC: 4829719. DOI: 10.1155/2016/6813016. View

20.

De Gennaro Colonna V, Bianchi M, Pascale V, Ferrario P, Morelli F, Pascale W . Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit. 2009; 15(4):RA91-101. View